Standardization of Nomenclature for the Mechanisms and Materials Utilized for Extracorporeal Blood Purification
- PMID: 37703868
- DOI: 10.1159/000533330
Standardization of Nomenclature for the Mechanisms and Materials Utilized for Extracorporeal Blood Purification
Abstract
In order to develop a standardized nomenclature for the mechanisms and materials utilized during extracorporeal blood purification, a consensus expert conference was convened in November 2022. Standardized nomenclature serves as a common language for reporting research findings, new device development, and education. It is also critically important to support patient safety, allow comparisons between techniques, materials, and devices, and be essential for defining and naming innovative technologies and classifying devices for regulatory approval. The multidisciplinary conference developed detailed descriptions of the performance characteristics of devices (membranes, filters, and sorbents), solute and fluid transport mechanisms, flow parameters, and methods of treatment evaluation. In addition, nomenclature for adsorptive blood purification techniques was proposed. This report summarizes these activities and highlights the need for standardization of nomenclature in the future to harmonize research, education, and innovation in extracorporeal blood purification therapies.
Keywords: Clearance; Dialysis; Filtration; Flux; Membrane characteristics; Renal replacement therapy.
© 2023 The Author(s). Published by S. Karger AG, Basel.
Conflict of interest statement
T.R. has received funding for lectures and has been consultant or advisory board member for AstraZeneca, B. Braun, Baxter, bioMérieux, Boehringer Ingelheim, Contatti (CytoSorbents), Eurofarma, Lifepharma, Medcorp, Medtronic, and Nova Biomedical. D.E.S., W.C., S.D.R., A.L., Z.R., J.A.K., and R.M. declare no competing interests. L.G.F. has received research support and lecture fees from Ortho Clinical Diagnostics, Baxter, ExThera, and bioMérieux and consulting fees from La Jolla Pharmaceuticals and Paion. G.V. has received lectures fees from Baxter. C.R. has been on the advisory board or speaker’s bureau for Asahi, Aferetica, AstraZeneca, Baxter, bioMérieux, CytoSorbents, GE, Jafron, Medica, and Medtronic. M.H.R. has received funding for lectures and has been consultant or advisory board member for AstraZeneca, Baxter, Reata, and Tavere.